ALX Oncology Holdings Inc.

14.62-0.5200-3.43%Vol 320.57K1Y Perf -77.08%
Aug 16th, 2022 16:00 DELAYED
BID14.02 ASK23.40
Open15.02 Previous Close15.14
Pre-Market- After-Market14.40
 - -  -0.22 -1.50%
Target Price
44.33 
Analyst Rating
Strong Buy 1.33
Potential %
203.22 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★★     56.99
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
11.68 
Earnings Rating
Market Cap595.72M 
Earnings Date
11th Aug 2022
Alpha-0.04 Standard Deviation0.28
Beta2.15 

Today's Price Range

14.500.00

52W Range

5.8281.19

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
14.31%
1 Month
41.12%
3 Months
49.95%
6 Months
-1.88%
1 Year
-77.08%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALXO14.62-0.5200-3.43
AAPL173.03-0.1600-0.09
GOOG122.51-0.3700-0.30
MSFT292.71-0.7600-0.26
XOM91.46-0.8600-0.93
WFC46.060.31000.68
JNJ167.571.48000.89
FB196.640.99000.51
GE81.071.26001.58
JPM123.631.17000.96
 
ProfitabilityValueIndustryS&P 500US Markets
9.10
-10 177.40
-10 159.60
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.66-0.81-22.73
Q01 2022-0.77-0.6022.08
Q04 2021-0.77-0.709.09
Q03 2021-0.47-0.61-29.79
Q02 2021-0.48-0.4016.67
Q01 2021-0.50-0.3530.00
Q04 2020-0.36-0.48-33.33
Q03 2020-0.37-0.355.41
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.66
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume320.57K
Shares Outstanding40.75K
Shares Float21.27M
Trades Count3.62K
Dollar Volume4.75M
Avg. Volume280.24K
Avg. Weekly Volume193.13K
Avg. Monthly Volume230.41K
Avg. Quarterly Volume417.19K

ALX Oncology Holdings Inc. (NASDAQ: ALXO) stock closed at 14.62 per share at the end of the most recent trading day (a -3.43% change compared to the prior day closing price) with a volume of 320.57K shares and market capitalization of 595.72M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 15 people. ALX Oncology Holdings Inc. CEO is Jaume Pons.

The one-year performance of ALX Oncology Holdings Inc. stock is -77.08%, while year-to-date (YTD) performance is -31.97%. ALXO stock has a five-year performance of %. Its 52-week range is between 5.82 and 81.19, which gives ALXO stock a 52-week price range ratio of 11.68%

ALX Oncology Holdings Inc. currently has a PE ratio of -5.30, a price-to-book (PB) ratio of 1.87, a price-to-sale (PS) ratio of 4 072.61, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -28.79%, a ROC of -30.56% and a ROE of -30.63%. The company’s profit margin is -%, its EBITDA margin is -10 159.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from ALX Oncology Holdings Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.66 for the next earnings report. ALX Oncology Holdings Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for ALX Oncology Holdings Inc. is Strong Buy (1.33), with a target price of $44.33, which is +203.22% compared to the current price. The earnings rating for ALX Oncology Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ALX Oncology Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ALX Oncology Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.45, ATR14 : 0.98, CCI20 : 234.48, Chaikin Money Flow : 0.30, MACD : 1.06, Money Flow Index : 68.43, ROC : 37.14, RSI : 71.69, STOCH (14,3) : 97.55, STOCH RSI : 1.00, UO : 71.28, Williams %R : -2.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ALX Oncology Holdings Inc. in the last 12-months were: Jason Lettmann (Sold 325 377 shares of value $8 901 804 ), Jaume Pons (Option Excercise at a value of $35 186), Jaume Pons (Sold 33 400 shares of value $2 148 927 ), Peter S. Garcia (Option Excercise at a value of $382 399), Peter S. Garcia (Sold 77 229 shares of value $5 511 853 ), Sophia Randolph (Option Excercise at a value of $312 376), Sophia Randolph (Sold 59 316 shares of value $3 142 813 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (83.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company. The firm is focused on developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.

CEO: Jaume Pons

Telephone: +1 650 466-7125

Address: 866 Malcolm Road, Burlingame 94010, CA, US

Number of employees: 15

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

63%38%

Bearish Bullish

69%31%


News

Stocktwits